Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression

Cancer Res (2022) 82 (4): 681–694.

https://doi.org/10.1158/0008-5472.CAN-21-3908

Published: 15 February 2022

View articletitled, An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression

Includes: Supplementary data

Journal Articles

Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0

Klazien W Matter-Walstra, Martin Bigler, Matthias Schwenkglenks, Daniela Bertschi, Jörg Brechbühl, Ursula Hasler-Strub, Roger von Moos, Andreas Müller, Ralph Winterhalder, Christoph Rochlitz

Cancer Res (2015) 75 (9_Supplement): P1-10-06.

https://doi.org/10.1158/1538-7445.SABCS14-P1-10-06

Published: 01 May 2015

View articletitled, Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0

Journal Articles

Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99

Cancer Res (2015) 75 (9_Supplement): P4-15-11.

https://doi.org/10.1158/1538-7445.SABCS14-P4-15-11

Published: 01 May 2015

View articletitled, Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99

Journal Articles

Breast Cancer Prevention: Lessons to be Learned from Mechanisms of Early Pregnancy–Mediated Breast Cancer Protection

Fabienne Meier-Abt, Mohamed Bentires-Alj, Christoph Rochlitz

Cancer Res (2015) 75 (5): 803–807.

https://doi.org/10.1158/0008-5472.CAN-14-2717

Published: 01 March 2015

View articletitled, Breast Cancer Prevention: Lessons to be Learned from Mechanisms of Early Pregnancy–Mediated Breast Cancer Protection

Journal Articles

Abstract 5714: Combination of glucagon-like-peptide-1 (GLP-1) receptor targeted therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Andreas Wicki, Damian Wild, Annette Orleth, Christoph Rochlitz, Christoph Mamot, Gerhard Christofori

Cancer Res (2012) 72 (8_Supplement): 5714.

https://doi.org/10.1158/1538-7445.AM2012-5714

Published: 15 April 2012

View articletitled, Abstract 5714: Combination of glucagon-like-peptide-1 (GLP-1) receptor targeted therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Journal Articles

Abstract 3634: Selective targeting of tumor-associated angiogenic tip and stalk cells with immunoliposomes (ILs) directed against VEGFR-2 and VEGFR-3 expressing cells

Andreas Wicki, Christoph Rochlitz, Annette Orleth, Reto Ritschard, Kari Alitalo, Richard Herrmann, Gerhard Christofori, Christoph Mamot

Cancer Res (2011) 71 (8_Supplement): 3634.

https://doi.org/10.1158/1538-7445.AM2011-3634

Published: 15 April 2011

View articletitled, Abstract 3634: Selective targeting of tumor-associated angiogenic tip and stalk cells with immunoliposomes (ILs) directed against VEGFR-2 and VEGFR-3 expressing cells

Journal Articles

Abstract #3669: Combined therapy with doxorubicin loaded vascular- and tumor-targeted immunoliposomes in wildtype and multidrug-resistant breast cancer xenografts

Matyas Ecsedi, Andreas Wicki, Reto Ritschard, Richard Herrmann, Christoph Rochlitz, Christoph Mamot

Cancer Res (2009) 69 (9_Supplement): 3669.

Published: 01 May 2009

View articletitled, Abstract #3669: Combined therapy with doxorubicin loaded vascular- and tumor-targeted immunoliposomes in wildtype and multidrug-resistant breast cancer xenografts

Journal Articles

Abstract #3657: Targeting of VEGFR-2 expressing endothelial cells with cytotoxic compounds as a novel anti-angiogenic approach

Andreas Wicki, Christoph Rochlitz, Reto Ritschard, Gerhard Christofori, Christoph Mamot

Cancer Res (2009) 69 (9_Supplement): 3657.

Published: 01 May 2009

View articletitled, Abstract #3657: Targeting of VEGFR-2 expressing endothelial cells with cytotoxic compounds as a novel anti-angiogenic approach

Journal Articles

Preliminary results of a phase I clinical trial of doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox ) in EGFR overexpressing solid tumors

Christoph Mamot, Reto Ritschard, Priska Stillhart, Richard Herrmann, Christoph Rochlitz

Cancer Res (2008) 68 (9_Supplement): 5743.

Published: 01 May 2008

View articletitled, Preliminary results of a phase I clinical trial of doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox ) in EGFR overexpressing solid tumors

Journal Articles

Bench to bedside development of anti-EGFR immunoliposomes for targeted drug delivery

Christoph Mamot, Reto Ritschard, Willy Kueng, John Park, Richard Herrmann, Christoph Rochlitz

Cancer Res (2007) 67 (9_Supplement): 1487.

Published: 01 May 2007

View articletitled, Bench to bedside development of anti-EGFR immunoliposomes for targeted drug delivery

Journal Articles

Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study.

Eilon D. Kirson, Vladimír Dbalý, Christoph Rochlitz, František Tovaryš, Marc Salzberg, Yoram Palti

Cancer Res (2006) 66 (8_Supplement): 1233.

Published: 15 April 2006

View articletitled, Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study.

Journal Articles

Anthracylines can bypass multidrug-resistance mechanisms via receptor-specific immunoliposomal delivery in EGFR overexpressing tumor cells

Christoph Mamot, Willy Kueng, Reto Ritschard, Richard Herrmann, John W. Park, Christoph Rochlitz

Cancer Res (2006) 66 (8_Supplement): 721–722.

Published: 15 April 2006

View articletitled, Anthracylines can bypass multidrug-resistance mechanisms via receptor-specific immunoliposomal delivery in EGFR overexpressing tumor cells

Journal Articles

Anti-EGFR immunoliposomes mediate specific and efficient drug delivery to target cells and can overcome multidrug-resistance

Christoph Mamot, Willy Kueng, Reto Ritschard, Juergen Reuter, Richard Herrmann, Charles Noble, Daryl Drummond, Dmitri Kirpotin, Christoph Rochlitz, John W. Park

Cancer Res (2005) 65 (9_Supplement): 334.

Published: 01 May 2005

View articletitled, Anti-EGFR immunoliposomes mediate specific and efficient drug delivery to target cells and can overcome multidrug-resistance

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression

Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0

Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99

Breast Cancer Prevention: Lessons to be Learned from Mechanisms of Early Pregnancy–Mediated Breast Cancer Protection

Abstract 5714: Combination of glucagon-like-peptide-1 (GLP-1) receptor targeted therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Abstract 3634: Selective targeting of tumor-associated angiogenic tip and stalk cells with immunoliposomes (ILs) directed against VEGFR-2 and VEGFR-3 expressing cells

Abstract #3669: Combined therapy with doxorubicin loaded vascular- and tumor-targeted immunoliposomes in wildtype and multidrug-resistant breast cancer xenografts

Abstract #3657: Targeting of VEGFR-2 expressing endothelial cells with cytotoxic compounds as a novel anti-angiogenic approach

Preliminary results of a phase I clinical trial of doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR ILs-dox ) in EGFR overexpressing solid tumors

Bench to bedside development of anti-EGFR immunoliposomes for targeted drug delivery

Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study.

Anthracylines can bypass multidrug-resistance mechanisms via receptor-specific immunoliposomal delivery in EGFR overexpressing tumor cells

Anti-EGFR immunoliposomes mediate specific and efficient drug delivery to target cells and can overcome multidrug-resistance

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only